Imbruvica

(Ibrutinib)

ApprovedSmall molecule

Ibrutinib is used to treat certain types of blood cancers, including chronic lymphocytic leukemia and mantle cell lymphoma, by slowing or stopping the growth of cancer cells.[2] Imbruvica is currently approved and in use across 74 indications[4].[1]

Imbruvica is one of 1198 small molecule programs targeting Pancreatic Neoplasm. It is currently in Approved.

Indications

310

Total Trials

Active Trials

1,197

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[4][1]

Indication

Pancreatic NeoplasmApproved

HIV InfectionActive, not recruiting

Non-Hodgkins LymphomaApproved

Lymphoplasmacytic LymphomaActive, not recruiting

MacroglobulinemiaActive, not recruiting

AnaphylaxisActive, not recruiting

Hemolytic AnemiaActive, not recruiting

Kidney CancerActive, not recruiting

Prolymphocytic LeukemiaApproved

Lung CancerApproved

Pancreatic NeoplasmApproved

Approved

HIV InfectionPhase 1

Active, not recruiting

Non-Hodgkins LymphomaApproved

Approved

Lymphoplasmacytic LymphomaPhase 2

Active, not recruiting

MacroglobulinemiaApproved

Active, not recruiting

AnaphylaxisPhase 2

Active, not recruiting

Hemolytic AnemiaPhase 2

Active, not recruiting

Kidney CancerPhase 1/Phase 2

Active, not recruiting

Prolymphocytic LeukemiaApproved

Approved

Lung CancerApproved

Approved

Showing 10 of 74 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Imbruvica

PPharmacyclics LLC.

Approved

1 2

Nolvadex

SSan Diego Pacific Oncology & Hematology Associates

Preclinical

78 3

Prolia

Amgen

Preclinical

14 4

Cymbalta

Alnylam Pharmaceuticals

Preclinical

3 5

Voltaren

Novartis

Preclinical

1 6

Lupron

EEastern Cooperative Oncology Group

Preclinical

5 7

Effexor

WWyeth-Lederle Vaccines

Preclinical

2 8

Chantix

PPrism Pharmaceuticals

Preclinical

1 9

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

1 10

Systemic Therapy

Bristol-Myers Squibb

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 1Active, not recruiting

Chronic Lymphocytic Leukemia

NCT02160015

Phase 2Recruiting

Richter's Transformation

NCT05672173

Q4 2026

Phase 1/2Recruiting

Central Nervous System Lymphoma

NCT03328078

Phase 1/2Active, not recruiting

Chronic Lymphocytic Leukemia

NCT03153202

Phase 1Active, not recruiting

Lymphoma

NCT03479268

Phase 2Active, not recruiting

Chronic Lymphocytic Leukemia

NCT02518555

Clinical

Trials by Indication[1]

Chronic Lymphocytic Leukemia37 trials

Ruxolitinib Combined With Ibrutinib in Chronic Lymphocytic Leukemia Patients

Unknown status·SSunnybrook Health Sciences Centre·Phase 1/2·NCT02912754·36 enrolled

A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Recruiting·VVA Office of Research and Development·Phase 2·NCT06520098·100 enrolled

Ofatumumab & Ibrutinib + Allogeneic Bone Marrow Transplant or Consolidation in High Risk Chronic Lymphocytic Leukemia

Completed·GGruppo Italiano Malattie EMatologiche dell'Adulto·Phase 2·NCT02388048·19 enrolled

Show 34 more trials

A Prospective, Multicenter, Phase-II Trial of Ibrutinib Plus Venetoclax in Patients With Creatinine Clearance >= 30 ml/Min Who Have Relapsed or Refractory Chronic Lymphocytic Leukemia (RR-CLL) With or Without TP53 Aberrations

Active, not recruiting·SStichting Hemato-Oncologie voor Volwassenen Nederland·Phase 2·NCT03226301·230 enrolled

Daratumumab and Ibrutinib in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia

Active, not recruiting·JJennifer Woyach·Phase 1·NCT03447808·15 enrolled

A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Completed·PPharmacyclics LLC.·Phase 3·NCT02264574·229 enrolled

Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01886859·27 enrolled

Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Active, not recruiting·JJennifer Woyach·Phase 2·NCT02518555·42 enrolled

Venetoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic Leukemia and Ibrutinib Resistance Mutations

Active, not recruiting·OOhio State University Comprehensive Cancer Center·Phase 2·NCT03513562·28 enrolled

A Multicenter Phase 2 Study of Ibrutinib in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) With 17p Deletion

Completed·PPharmacyclics LLC.·Phase 2·NCT01744691·145 enrolled

A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Active, not recruiting·—·Phase 1·NCT02537613·54 enrolled

Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation

Withdrawn·MM.D. Anderson Cancer Center·Phase 1·NCT04781855

Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)

Completed·PPharmacyclics LLC.·Phase 2·NCT02910583·323 enrolled

Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.

Completed·UUniversity of California, San Diego·Phase 1/2·NCT02315768·32 enrolled

Clinical-biological Characteristics and Outcome of Chronic Lymphocytic Leukemia Under Ibrutinib-named Patient Program

Completed·GGruppo Italiano Malattie EMatologiche dell'Adulto··NCT02582320·264 enrolled

PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia

Active, not recruiting·KKami Maddocks, MD·Phase 2·NCT01589302·154 enrolled

Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Participants With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL)

Completed·TTG Therapeutics, Inc.·Phase 3·NCT02301156·126 enrolled

Identification of Biomarkers That Are Predictive of Early Ibrutinib Treatment Failure in High Risk TP53 Mutated Chronic Lymphocytic Leukemia

Completed·OOncology Institute of Southern Switzerland··NCT02827617·56 enrolled

Obinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib.

Withdrawn·MMichael Choi·Phase 1·NCT02611908

Ibrutinib and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia After Ibrutinib Resistance

Withdrawn·KKerry Rogers·Phase 2·NCT03943342

Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell Transplant

Withdrawn·FFred Hutchinson Cancer Center·Phase 2·NCT02662296

A Study of Ibrutinib in the Treatment of Chronic Lymphocytic Leukemia and Mantle-cell Lymphoma in Routine Clinical Practice

Completed· Johnson & Johnson logo

Johnson & Johnson··NCT03425591·508 enrolled

Ibrutinib in Previously Untreated Binet Stage a Chronic Lymphocytic Leukemia with Risk of Disease Progression

Completed·GGerman CLL Study Group·Phase 3·NCT02863718·515 enrolled

A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Recruiting· Eli Lilly logo

Eli Lilly·Phase 3·NCT05254743·662 enrolled

Ibrutinib, Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic Leukemia

Completed·GGrupo Cooperativo de Hemopatías Malignas·Phase 2·NCT03755947·3 enrolled

Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT02160015·12 enrolled

A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia

Completed· BeiGene logo

BeiGene·Phase 3·NCT03734016·652 enrolled

Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL)

Active, not recruiting·JJoshua Brody·Phase 1/2·NCT03153202·23 enrolled

Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax

Terminated·TTG Therapeutics, Inc.·Phase 2·NCT04016805·41 enrolled

Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)

Active, not recruiting·AAcerta Pharma BV·Phase 3·NCT02477696·533 enrolled

Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Completed·PPharmacyclics LLC.·Phase 3·NCT01724346·269 enrolled

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Completed· AbbVie logo

AbbVie·Phase 2·NCT05105841·20 enrolled

Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT02629809·81 enrolled

Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Terminated·EEmory University·Phase 1·NCT02614508·1 enrolled

Clinical Outcomes of Chronic Lymphocytic Leukemia (CCL) and Mantle Cell Lymphoma (MCL) Participants Treated With Ibrutinib: A Medical Chart Review From India

Completed·JJohnson & Johnson Private Limited··NCT03476655·40 enrolled

A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Completed·PPharmacyclics LLC.·Phase 3·NCT01578707·391 enrolled

Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 3·NCT01886872·547 enrolled

Mantle Cell Lymphoma23 trials

Dose Finding Study of Ibrutinib Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma

Active, not recruiting·HHackensack Meridian Health·Phase 1·NCT02446236·27 enrolled

Ibrutinib in Treating Participants With Untreated High Risk Smoldering Mantle Cell Lymphoma

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT03282396·20 enrolled

A Trial of Obinutuzumab,GDC-0199 Plus Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma Patients

Completed·NNantes University Hospital·Phase 1/2·NCT02558816·48 enrolled

Show 20 more trials

Study of Ibrutinib (a Bruton's Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT01646021·280 enrolled

Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma

Terminated·AADC Therapeutics S.A.·Phase 1/2·NCT03684694·136 enrolled

A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT01599949·120 enrolled

Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)

Active, not recruiting· Eli Lilly logo

Eli Lilly·Phase 3·NCT04662255·500 enrolled

A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma

Withdrawn·OOncternal Therapeutics, Inc·Phase 3·NCT05431179

ABT-199 & Ibrutinib in Mantle Cell Lymphoma (AIM)

Unknown status·PPeter MacCallum Cancer Centre, Australia·Phase 2·NCT02471391·37 enrolled

Ibrutinib Plus Rituximab and Lenalidomide in Treating Elderly Participants With Newly Diagnosed Mantle Cell Lymphoma

Withdrawn·MM.D. Anderson Cancer Center·Phase 2·NCT03232307

Bortezomib in Combination With Ibrutinib in Ibrutinib Relapsed Mantle Cell Lymphoma

Withdrawn·UUniversity of Michigan Rogel Cancer Center·Phase 2·NCT03617484

A Study of Copanlisib and Ibrutinib in Mantle Cell Lymphoma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1/2·NCT03877055·8 enrolled

Trial of PCI-32765 (BTK Inhibitor) in Combination With Carfilzomib in Relapse/Refractory Mantle Cell Lymphoma

Terminated·MM.D. Anderson Cancer Center·Phase 1·NCT02269085·8 enrolled

Patient-Derived Xenografts in Personalizing Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT03219047·1 enrolled

Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT02427620·131 enrolled

CAR-T-cell Treatment for Untreated High Risk MANtle Cell Lymphoma

Recruiting·—·Phase 2·NCT06482684·150 enrolled

Ibrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell Lymphoma

Unknown status·NNorthwestern University·Phase 2·NCT02242097·37 enrolled

Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma

Active, not recruiting·TThe Lymphoma Academic Research Organisation·Phase 2·NCT04802590·194 enrolled

ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma

Recruiting·PProf. Dr. M. Dreyling (co-chairman)·Phase 3·NCT02858258·870 enrolled

Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT03710772·51 enrolled

Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial

Recruiting·OOHSU Knight Cancer Institute·Phase 1/2·NCT06357676·27 enrolled

Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell Lymphoma

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT02159755·28 enrolled

Study to Assess Effect of Oral Venetoclax Tablet in Combination With Oral Ibrutinib Capsule on Best Overall Response of Complete Response in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma

Completed· AbbVie logo

AbbVie·Phase 2·NCT04477486·13 enrolled

Lymphoma20 trials

A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT02756247·37 enrolled

Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT02309580·14 enrolled

Bruton's Tyrosine Kinase (BTK) Inhibition in B-cell Lymphomas

Terminated·TThe Lymphoma Academic Research Organisation·Phase 1·NCT02055924·85 enrolled

Show 17 more trials

A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas

Completed·PPharmacyclics LLC.·Phase 1/2·NCT02401048·61 enrolled

Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Completed·KKami Maddocks·Phase 1·NCT02950220·2 enrolled

Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma

Recruiting·CCanadian Cancer Trials Group·Phase 2·NCT05998642·30 enrolled

Ibrutinib With Methotrexate and Temozolomide for Patients With Newly Diagnosed Primary CNS Lymphoma

Unknown status·HHuiqiang Huang·Phase 2·NCT04514393·33 enrolled

Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma

Active, not recruiting·CCanadian Cancer Trials Group·Phase 2·NCT02436707·129 enrolled

Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma

Withdrawn· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT02743546

Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant

Completed·VVanderbilt-Ingram Cancer Center·Phase 2·NCT02869633·23 enrolled

A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma

Terminated· Takeda logo

Takeda·Phase 1·NCT02954406·43 enrolled

MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas

Active, not recruiting·IInternational Extranodal Lymphoma Study Group (IELSG)·Phase 2·NCT03697512·175 enrolled

A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma

Terminated· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT02703272·72 enrolled

Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

Recruiting·YYazeed Sawalha·Phase 1/2·NCT06536049·38 enrolled

Ibrutinib Post Stem Cell Transplantation (SCT) in Double-Hit B-Cell Lymphoma

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT02272686·1 enrolled

Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma

Active, not recruiting·—·Phase 1·NCT03479268·18 enrolled

Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone Lymphoma

Completed·PPharmacyclics LLC.·Phase 2·NCT01980628·63 enrolled

Ibrutinib in Relapsed Nodular Lymphocyte-predominant Hodgkin Lymphoma (NLPHL)

Completed·UUniversity of Cologne·Phase 2·NCT02626884·14 enrolled

Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS)

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT03964090·48 enrolled

Phase II Study of Ibrutinib in Patients With Relapsed or Refractory Marginal Zone Lymphoma

Terminated·NNational Cancer Centre, Singapore·Phase 2·NCT03093831·5 enrolled

Diffuse Large B-Cell Lymphoma12 trials

Study of Ibrutinib in Combination With Rituximab-CHOP in Epstein-Barr Virus-positive Diffuse Large B-cell Lymphoma

Completed·SSamsung Medical Center·Phase 2·NCT02670616·24 enrolled

A Study of ABT-199 Plus Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Terminated·HHackensack Meridian Health·Phase 1·NCT03136497·10 enrolled

Ibrutinib in Patients With Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma Non-candidates to ASCT

Completed·GGrupo Español de Linfomas y Transplante Autólogo de Médula Ósea·Phase 2·NCT02692248·64 enrolled

Show 9 more trials

A Study of Itacitinib (INCB039110) in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Completed· Incyte logo

Incyte·Phase 1/2·NCT02760485·33 enrolled

Ibrutinib and Standard Immuno-Chemotherapy in Younger, High-Risk Patients With Diffuse Large B-Cell Lymphoma

Completed·UUniversity Hospital Muenster·Phase 2·NCT03399513·40 enrolled

Safety and Efficacy Study of a BTK Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Completed·PPharmacyclics LLC.·Phase 2·NCT01325701·78 enrolled

Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma

Completed·—·Phase 1·NCT03440567·16 enrolled

Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)

Withdrawn·KKaryopharm Therapeutics Inc·Phase 1/2·NCT04607772

Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Completed·PPharmacyclics LLC.·Phase 1/2·NCT02142049·35 enrolled

TGR-1202 and Ibrutinib in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Completed·UUniversity of Nebraska·Phase 2·NCT02874404·13 enrolled

Ibrutinib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT02219737·26 enrolled

Study of Tisagenlecleucel in Combination With Ibrutinib in r/r Diffuse Large B-cell Lymphoma Patients

Terminated· Novartis logo

Novartis·Phase 1·NCT03876028·10 enrolled

Central Nervous System Lymphoma7 trials

Nivolumab and Ibrutinib in Treating Patients With Relapsed or Refractory Central Nervous System Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT03770416·18 enrolled

Copanlisib With Ibrutinib for Patients With Recurrent/ Refractory Primary Central Nervous System Lymphoma (PCNSL)

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1/2·NCT03581942·18 enrolled

Ibrutinib With Rituximab and Lenalidomide for Patients With Recurrent/Refractory Primary or Secondary Central Nervous System Lymphoma (PCNSL/SCNSL)

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT03703167·25 enrolled

Show 4 more trials

CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

Recruiting·CCuris, Inc.·Phase 1/2·NCT03328078·152 enrolled

A Trial to Compare Ibrutinib Versus Lenalidomide in Combination With MRE-chemotherapy for Adult Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL)

Unknown status·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT04129710·120 enrolled

Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1/2·NCT02315326·93 enrolled

A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT07082868·26 enrolled

66 more indications

Macroglobulinemia6 trials

Efficacy of First Line B-RI for Treatment Naive Waldenström's Macroglobulinemia

Active, not recruiting·CChristian Buske·Phase 2·NCT03620903·53 enrolled

Ibrutinib Followed by BR (Bendamustine and Rituximab) as a Time-Limited Therapy for Waldenström Macroglobulinemia

Not yet recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 1·NCT07169565·21 enrolled

A Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4 Waldenstrom's Macroglobulinemia

Terminated·—·Phase 1·NCT03225716·13 enrolled

Show 3 more trials

A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4

Completed·XX4 Pharmaceuticals·Phase 1·NCT04274738·16 enrolled

A Study of Ibrutinib in Combination With Rituximab, in Japanese Participants With Waldenstrom's Macroglobulinemia (WM)

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT04062448·16 enrolled

Daratumumab Plus Ibrutinib in Patients With Waldenstrӧm's Macroglobulinemia

Terminated·WWeill Medical College of Cornell University·Phase 2·NCT03679624·1 enrolled

Treatment5 trials

CLL Induction Treatment With Venetoclax and Ibrutinib, Followed by Ibrutinib and Obinutuzumab in Patients With MRD.

Active, not recruiting·SStichting Hemato-Oncologie voor Volwassenen Nederland·Phase 2·NCT04639362·85 enrolled

Fixed-duration Therapy With Ibrutinib and Obinutuzumab (GA-101) in Treatment-naïve Patients With CLL

Recruiting·PPaolo Ghia·Phase 2·NCT04908228·53 enrolled

A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Treatment-Naive CLL

Active, not recruiting·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 2·NCT02514083·29 enrolled

Show 2 more trials

Combination of Ibrutinib and As2O3 in the Treatment of CLL

Unknown status·PPeking University People's Hospital·Phase 3·NCT02757040·70 enrolled

Biomarker Guided Treatment in DLBCL

Unknown status·RRuijin Hospital·Phase 2·NCT04025593·128 enrolled

Follicular Lymphoma5 trials

Study of Ibrutinib in Combination With Rituximab in Previously Untreated Subjects With Follicular Lymphoma

Completed·PPharmacyclics LLC.·Phase 2·NCT01980654·80 enrolled

Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT02532257·48 enrolled

Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma

Completed·PPharmacyclics LLC.·Phase 3·NCT02947347·445 enrolled

Show 2 more trials

Rituximab With or Without Ibrutinib for Patients With Advanced Follicular Lymphoma

Terminated·SSwiss Cancer Institute·Phase 2·NCT02451111·190 enrolled

Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma

Recruiting·JJoseph Tuscano·Phase 2·NCT04450173·40 enrolled

Multiple Myeloma5 trials

Study of BTK Inhibitor, Ibrutinib in Combination With Carfilzomib in Subjects With Relapsed and Refractory Multiple Myeloma

Completed·PPharmacyclics LLC.·Phase 1/2·NCT01962792·84 enrolled

Study of Ibrutinib in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed/Relapsed and Refractory Multiple Myeloma

Completed·PPharmacyclics Switzerland GmbH·Phase 2·NCT02902965·74 enrolled

Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients

Terminated·IIcahn School of Medicine at Mount Sinai·Phase 2·NCT02943473·9 enrolled

Show 2 more trials

Ibrutinib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Ineligible for Transplant

Terminated·MMayo Clinic·Phase 1·NCT03015792·18 enrolled

Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma

Completed·AAlliance Foundation Trials, LLC.·Phase 1·NCT03702725·14 enrolled

Relapsed/Refractory3 trials

Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL

Completed·SSteven E. Coutre·Phase 2·NCT03045328·22 enrolled

Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL

Recruiting· Ascentage Pharma Group Inc. logo

Ascentage Pharma Group Inc.·Phase 1/2·NCT04494503·123 enrolled

Intravenous BI 836826 in Combination With Ibrutinib in Relapsed/Refractory CLL Patients Who Have Been Pre-treated With at Least One Prior Line of Systemic Therapy, and Who Are Eligible for Treatment With Ibrutinib

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02759016·7 enrolled

Chronic Graft Versus Host Disease3 trials

A Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Steroid Dependent/Refractory Chronic Graft Versus Host Disease (cGVHD)

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT03474679·19 enrolled

Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Participants With New Onset Chronic Graft Versus Host Disease (cGVHD)

Completed·PPharmacyclics LLC.·Phase 3·NCT02959944·193 enrolled

Ibrutinib for the Prevention of Chronic Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant

Recruiting·MMayo Clinic·Phase 2·NCT06271616·40 enrolled

Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma3 trials

Multicenter Study of Pacritinib Combined With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Withdrawn·UUniversity of Michigan Rogel Cancer Center·Phase 1/2·NCT02677948

Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 2·NCT03204188·15 enrolled

A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT02406742·47 enrolled

CLL3 trials

Copanlisib Plus Ibrutinib or Acalabrutinib in R/R CLL

Withdrawn·IInhye Ahn·Phase 2·NCT04685915

Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLL

Terminated·SSwiss Cancer Institute·Phase 2·NCT03708003·30 enrolled

VAY736 in Combination With Ibrutinib in Patients With CLL on Ibrutinib

Terminated· Novartis logo

Novartis·Phase 1·NCT03400176·39 enrolled

Richter's Transformation2 trials

Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation

Recruiting·—·Phase 2·NCT05672173·20 enrolled

Study of Ibrutinib & Obinutuzumab With/Without CHOP for Richter's Transformation or Richter's Syndrome Patients

Terminated·NNorthwell Health·Phase 2·NCT03145480·3 enrolled

Refractory2 trials

Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies

Unknown status·CChinese Academy of Medical Sciences·Phase 2·NCT04994626·20 enrolled

Combination of BTK Inhibitor Overcomes Drug-resistance in Refractory/Relapsed FLT3 Mutant AML

Unknown status·NNanfang Hospital, Southern Medical University·Phase 2/3·NCT03642236·122 enrolled

Relapse2 trials

RICE-ibrutinib in Relapsed DLBCL

Unknown status·SSingapore General Hospital·Phase 2·NCT02955628·34 enrolled

ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL

Active, not recruiting·—·Phase 1·NCT02787369·3 enrolled

Leukemia2 trials

Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT02756897·234 enrolled

A Study of PCI-32765 (Ibrutinib) Versus Rituximab in Relapsed or Refractory Chronic Leukemia/Lymphoma

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT01973387·160 enrolled

COVID-192 trials

Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19)

Withdrawn·—·Phase 2·NCT04665115

Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization

Completed·JJennifer Woyach·Phase 1·NCT04439006·10 enrolled

Hemolytic Anemia2 trials

The Safety and Efficacy of Ibrutinib in Refractory/Relapsed Autoimmune Hemolytic Anemia

Active, not recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT04398459·18 enrolled

Ibrutinib in Steroid Refractory Autoimmune Hemolytic Anemia

Unknown status·EEugene Nikitin·Phase 2·NCT03827603·50 enrolled

B-cell Malignancies2 trials

Ublituximab + Ibrutinib in Select B-cell Malignancies

Completed·TTG Therapeutics, Inc.·Phase 1/2·NCT02013128·66 enrolled

ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies

Withdrawn·—·Phase 1·NCT04043845

Acute Myeloid Leukemia2 trials

Ibrutinib, Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Terminated·SSteven E. Coutre·Phase 1·NCT02635074·2 enrolled

Study of Ibrutinib in Subjects With Acute Myeloid Leukemia

Terminated·PPharmacyclics LLC.·Phase 2·NCT02351037·36 enrolled

Acute Lymphoblastic Leukemia2 trials

Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia

Recruiting·BBrian Jonas·Phase 2·NCT02997761·20 enrolled

Study of Pts With Philadelphia Chromosome-Pos ALL With Comb of Ibrutinib, Dasatinib, and Prednisone

Withdrawn·UUniversity of Utah·Phase 1·NCT02815059

Myelodysplastic Syndrome2 trials

Ibrutinib and Lenalidomide in Treating Patients With Myelodysplastic Syndrome

Completed·UUniversity of California, Davis·Phase 1·NCT03359460·4 enrolled

Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome

Completed·BBrian Jonas·Phase 1·NCT02553941·21 enrolled

Waldenstrom macroglobulinemia1 trial

Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia

Terminated·MMayo Clinic·Phase 2·NCT03506373·21 enrolled

Interaction1 trial

A Drug Interaction Study to Assess the Effect of Omeprazole on the Pharmacokinetics of Ibrutinib in Healthy Adults

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT02638116·20 enrolled

Tics1 trial

A Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of Ibrutinib in Healthy Participants

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT01626651·21 enrolled

Completed·OOncternal Therapeutics, Inc·Phase 1/2·NCT03088878·95 enrolled

Metastatic1 trial

Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCC

Active, not recruiting·UUniversity of California, San Diego·Phase 2·NCT03646461·5 enrolled

Atrial Fibrillation1 trial

Unknown status·UUniversity Hospital, Caen··NCT06224452·18,000 enrolled

Immune1 trial

Autoimmune Cytopenia and BcR Inhibitors

Unknown status·IInstitut Paoli-Calmettes··NCT03469895·40 enrolled

Elderly Patients1 trial

Ibrutinib, Bortezomib and Rituximab-CHOP for the Treatment of Elderly Patients With CD20+ DLBCL, IPI ≥ 2

Completed·PProf. Dr. Clemens Schmitt·Phase 1/2·NCT03129828·38 enrolled

Age1 trial

Venetoclax With High-dose Ibrutinib for CLL Progressing on Single Agent Ibrutinib

Active, not recruiting·MMichael Choi·Phase 1·NCT03422393·24 enrolled

Prostate Cancer1 trial

Ibrutinib as Neoadjuvant Therapy in Localized Prostate Cancer

Completed·WWashington University School of Medicine·Phase 2·NCT02643667·27 enrolled

Absorption1 trial

A Study to Determine the Absorption, Metabolism, and Routes of Excretion of (14C) Radiolabeled Ibrutinib in Healthy Male Participants

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT01674322·6 enrolled

Chronic Hepatitis1 trial

Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers

Unknown status·TThe University of Hong Kong·Phase 3·NCT02991638·62 enrolled

Glioblastoma1 trial

Ibrutinib With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma

Active, not recruiting·—·Phase 1·NCT03535350·36 enrolled

Brain Cancer1 trial

Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer

Recruiting·TTheodore S. Johnson·Phase 1·NCT05106296·37 enrolled

Phase II1 trial

Phase II Trial GA101 Inbrutinib B CLL

Completed·FFrench Innovative Leukemia Organisation·Phase 2·NCT02666898·135 enrolled

ESS1 trial

Study to Assess the Bioequivalence of Ibrutinib 140 Milligram (mg) Tablet to 140 mg IMBRUVICA Capsule

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT02877225·103 enrolled

Kidney Cancer1 trial

Ibrutinib and Nivolumab in Treating Patients With Previously-Treated Metastatic Kidney Cancer

Completed·UUniversity of California, Davis·Phase 1/2·NCT02899078·31 enrolled

Trial1 trial

Trial of Ibrutinib Plus Venetoclax Plus Obinutuzumab in Patients With CLL

Completed·UUniversity of Ulm·Phase 2·NCT02758665·41 enrolled

Metastatic Solid Tumors1 trial

Ibrutinib and Nivolumab in Treating Participants With Metastatic Solid Tumors

Completed·OOhio State University Comprehensive Cancer Center·Phase 1·NCT03525925·16 enrolled

Lenalidomide1 trial

Smart Start: A Phase II Study of Rituximab, Lenalidomide, and Ibrutinib

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT02636322·60 enrolled

Chronic GVHD1 trial

Ibrutinib and Rituxan for Chronic GVHD

Terminated·NNorthside Hospital, Inc.·Phase 2·NCT04235036·15 enrolled

Non-Small Cell Lung Cancer1 trial

A Phase I/II Study of Ibrutinib in Previously Treated Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT02321540·13 enrolled

Severe Acute Respiratory Syndrome1 trial

Study of Oral Ibrutinib Capsules to Assess Respiratory Failure in Adult Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Pulmonary Injury

Completed· AbbVie logo

AbbVie·Phase 2·NCT04375397·46 enrolled

Refractory Solid Tumors1 trial

A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors

Completed·PPharmacyclics LLC.·Phase 1/2·NCT02403271·124 enrolled

B-cell NHL1 trial

A Study of the MALT1 Inhibitor JNJ-67856633 and Ibrutinib in Combination in B-cell NHL and CLL

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT04876092·45 enrolled

Clinical Trial1 trial

PRECISE CURATE.AI Pilot Clinical Trial

Unknown status·NNational University Hospital, Singapore·Phase 1/2·NCT04522284·20 enrolled

Pancreatic Neuroendocrine Tumor1 trial

Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT02575300·20 enrolled

Bone Marrow Transplantation1 trial

A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)

Completed· Incyte logo

Incyte·Phase 3·NCT03112603·330 enrolled

Hematologic Malignancies1 trial

A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies

Completed· Sumitomo Pharma America, Inc. logo

Sumitomo Pharma America, Inc.·Phase 1·NCT02352558·15 enrolled

Chronic Lymphocytic Leukaemia (CLL)1 trial

Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients with Previously Untreated Chronic Lymphocytic Leukaemia (CLL)

Active, not recruiting·GGerman CLL Study Group·Phase 3·NCT04608318·897 enrolled

Hairy Cell Leukemia1 trial

Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT01841723·44 enrolled

B-cell acute lymphoblastic leukemia1 trial

Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT02129062·3 enrolled

TIA1 trial

Sequential Regimen of Bendamustin [B] Followed by GA101 and Ibrutinib [I] in CLL Patients

Completed·GGerman CLL Study Group·Phase 2·NCT02345863·66 enrolled

DLBCL1 trial

Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL

Active, not recruiting· Novartis logo

Novartis·Phase 1/2·NCT03960840·217 enrolled

MRD1 trial

Mosunetuzumab for CLL MRD Clearance

Recruiting·IInhye Ahn·Phase 1/2·NCT07052695·40 enrolled

B-cell Malignancy1 trial

Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell Malignancy

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT02381080·26 enrolled

Breast Cancer1 trial

Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer

Active, not recruiting·UUS Oncology Research·Phase 1/2·NCT03379428·34 enrolled

High Risk1 trial

Phase II Study About Combination CHOP-21, Obinutuzumab and Ibrutinib in Untreated Young High Risk DLBCL Patients.

Terminated·FFondazione Italiana Linfomi - ETS·Phase 2·NCT02670317·1 enrolled

CHOP1 trial

Ibrutinib + R-CHOP Followed by Ibrutinib Maintenance

Active, not recruiting·FFondazione Italiana Linfomi - ETS·Phase 2·NCT03731234·75 enrolled

Gastric Carcinoma1 trial

Proof-of-concept Study of Ibrutinib in c-MYC and HER2 Amplified Oesophagogastric Carcinoma

Unknown status·RRoyal Marsden NHS Foundation Trust·Phase 2·NCT02884453·17 enrolled

Pembrolizumab1 trial

Pembrolizumab, Ibrutinib and Rituximab in PCNSL

Recruiting·—·Phase 1/2·NCT04421560·37 enrolled

Safety and Efficacy1 trial

Study Evaluating the Safety and Efficacy of iR2 in Untreated and Unfit Elderly Patients With DLBCL

Unknown status·RRuijin Hospital·Phase 2·NCT03949062·30 enrolled

Amyloidosis1 trial

Ibrutinib With or Without Bortezomib and Dexamethasone in Treating Patients With Relapsed or Refractory Immunoglobulin Light Chain Amyloidosis

Withdrawn·MMayo Clinic·Phase 2·NCT03130348

Cutaneous Melanoma1 trial

Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT02581930·18 enrolled

Anaphylaxis1 trial

Inhibition of Anaphylaxis by Ibrutinib

Completed·—·Phase 2·NCT03149315·6 enrolled

Unspecified1 trial

Protocol GELLC-7: Ibrutinib Followed by Ibrutinib Consolidation in Combination With Ofatumumab

Unknown status·PPETHEMA Foundation·Phase 2·NCT03280160·84 enrolled

Regulatory

FDA Approval Timeline[5]

Dec 20, 2017

IMBRUVICA

NDA NDA205552

Feb 16, 2018

IMBRUVICA

NDA NDA210563

Aug 24, 2022

IMBRUVICA

NDA NDA217003

Sources

References

[1]
ClinicalTrials.gov — 310 trial records for Ibrutinib. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Imbruvica drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Ibrutinib compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Ibrutinib. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA217003). U.S. Food & Drug Administration.
[6]
FDA Orange Book — Patent and exclusivity data for Imbruvica. U.S. Food & Drug Administration.
[7]
SEC EDGAR — Pharmacyclics LLC. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Tyrosine-Protein Kinase BTK Inhibitor[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: PPharmacyclics LLC.

Patent Landscape[6]

Patent Cliff

Dec 28, 2026

Earliest patent expiration — generic entry possible after this date

Patent #Expires

8754091Dec 28, 2026

8703780Dec 28, 2026

8697711Dec 28, 2026

8952015Dec 28, 2026

8497277Dec 28, 2026

79 more patents

8476284Dec 28, 2026

7514444Dec 28, 2026

8735403Dec 28, 2026

8957079Dec 28, 2026

9181257Dec 28, 2026

8563563Apr 26, 2027

8952015*PEDJun 28, 2027

8697711*PEDJun 28, 2027

8703780*PEDJun 28, 2027

8735403*PEDJun 28, 2027

8497277*PEDJun 28, 2027

8957079*PEDJun 28, 2027

9181257*PEDJun 28, 2027

8476284*PEDJun 28, 2027

8754091*PEDJun 28, 2027

7514444*PEDJun 28, 2027

8563563*PEDOct 26, 2027

8008309Nov 13, 2027

8008309*PEDMay 13, 2028

9801883Jun 3, 2031

10653696Jun 3, 2031

11672803Jun 3, 2031

10016435Jun 3, 2031

10478439Jun 3, 2031

10751342Jun 3, 2031

10004746Jun 3, 2031

9125889Jun 3, 2031

9814721Jun 3, 2031

9801881Jun 3, 2031

8754090Jun 3, 2031

8999999Jun 3, 2031

9125889*PEDDec 3, 2031

10016435*PEDDec 3, 2031

10478439*PEDDec 3, 2031

8754090*PEDDec 3, 2031

10653696*PEDDec 3, 2031

8999999*PEDDec 3, 2031

9814721*PEDDec 3, 2031

9801881*PEDDec 3, 2031

9801883*PEDDec 3, 2031

10004746*PEDDec 3, 2031

10751342*PEDDec 3, 2031

10752634Jun 3, 2033

10961251Jun 3, 2033

10125140Jun 3, 2033

10106548Jun 3, 2033

9725455Jun 3, 2033

9713617Jun 3, 2033

10294231Jun 3, 2033

10294232Jun 3, 2033

9540382Aug 18, 2033

9296753Oct 30, 2033

10294231*PEDDec 3, 2033

9725455*PEDDec 3, 2033

10752634*PEDDec 3, 2033

10106548*PEDDec 3, 2033

10125140*PEDDec 3, 2033

10294232*PEDDec 3, 2033

10961251*PEDDec 3, 2033

9713617*PEDDec 3, 2033

9540382*PEDFeb 18, 2034

9296753*PEDApr 30, 2034

9795604Oct 24, 2034

10463668Oct 24, 2034

10695350Oct 24, 2034

9795604*PEDApr 24, 2035

10463668*PEDApr 24, 2035

10695350*PEDApr 24, 2035

9655857Mar 3, 2036

12551448Mar 3, 2036

10828259Mar 3, 2036

10010507Mar 3, 2036

10213386Mar 3, 2036

12364698Apr 6, 2036

10010507*PEDSep 3, 2036

10213386*PEDSep 3, 2036

10828259*PEDSep 3, 2036

9655857*PEDSep 3, 2036

12201690Jun 14, 2039

Imbruvica

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2026

Trials by Indication[1]

Chronic Lymphocytic Leukemia37 trials

Mantle Cell Lymphoma23 trials

Lymphoma20 trials

Diffuse Large B-Cell Lymphoma12 trials

Central Nervous System Lymphoma7 trials

Macroglobulinemia6 trials

Treatment5 trials

Follicular Lymphoma5 trials

Multiple Myeloma5 trials

Relapsed/Refractory3 trials

Chronic Graft Versus Host Disease3 trials

Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma3 trials

CLL3 trials

Richter's Transformation2 trials

Refractory2 trials

Relapse2 trials

Leukemia2 trials

COVID-192 trials

Hemolytic Anemia2 trials

B-cell Malignancies2 trials

Acute Myeloid Leukemia2 trials

Acute Lymphoblastic Leukemia2 trials

Myelodysplastic Syndrome2 trials

Waldenstrom macroglobulinemia1 trial

Interaction1 trial

Tics1 trial

Observational Study1 trial

Prospective1 trial

B-cell Lymphoid Malignancies1 trial

Metastatic1 trial

Atrial Fibrillation1 trial

Immune1 trial

Elderly Patients1 trial

Age1 trial

Prostate Cancer1 trial

Absorption1 trial

Chronic Hepatitis1 trial

Glioblastoma1 trial

Brain Cancer1 trial

Phase II1 trial

ESS1 trial

Kidney Cancer1 trial

Trial1 trial

Metastatic Solid Tumors1 trial

Lenalidomide1 trial

Chronic GVHD1 trial

Non-Small Cell Lung Cancer1 trial

Severe Acute Respiratory Syndrome1 trial

Refractory Solid Tumors1 trial

B-cell NHL1 trial

Clinical Trial1 trial

Pancreatic Neuroendocrine Tumor1 trial

Bone Marrow Transplantation1 trial

Hematologic Malignancies1 trial

Chronic Lymphocytic Leukaemia (CLL)1 trial

Hairy Cell Leukemia1 trial

B-cell acute lymphoblastic leukemia1 trial

TIA1 trial

DLBCL1 trial

MRD1 trial

B-cell Malignancy1 trial

Breast Cancer1 trial

High Risk1 trial

CHOP1 trial

Gastric Carcinoma1 trial

Pembrolizumab1 trial

Safety and Efficacy1 trial

Amyloidosis1 trial

Cutaneous Melanoma1 trial

Anaphylaxis1 trial

Unspecified1 trial

FDA Approval Timeline[5]

References